NCT05437419 - A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

July 27, 2023

Conditions

Rheumatoid Arthritis

Interventions

DRUG

TCK-276

Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.

DRUG

TCK-276 Placebo

Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.

Trial Locations (8)

Clinical Site Partners, LLC dba CSP Orlando, Winter Park

San Marcus Research Clinic, Inc., Miami Lakes

Floridian Clinical Research, LLC, Miami Lakes

SouthCoast Research Center, Inc, Miami

Allied Biomedical Research Institute, Miami

St. Jude Clinical Research, LLC, Doral

SMS Clinical Research, LLC, Mesquite

Orange County Research Center, Tustin